Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ: BBIO )

32.97 +0.66 (+2.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,577,570
Open 32.59
Bid (Size) 32.88 (18)
Ask (Size) 32.97 (33)
Prev. Close 32.31
Today's Range 32.42 - 33.45
52wk Range 21.62 - 39.47
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
+16.91%
+16.91%
1 Month
+4.47%
+4.47%
3 Month
+18.98%
+18.98%
6 Month
+25.89%
+25.89%
1 Year
+19.63%
+19.63%

More News

Read More
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For February 20, 2025
Via Benzinga
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Top 4 Health Care Stocks You May Want To Dump In Q1
Via Benzinga
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
BridgeBio Pharma Stock Earns 87 RS Rating
Via Investor's Business Daily
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Via Investor's Business Daily
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Via Benzinga
Topics Economy
Exposures Fossil Fuels Interest Rates
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Via Benzinga
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
Via Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Via Benzinga
Exposures Product Safety
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Via Benzinga
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.